TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03813199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 50mg
Description: ABX464 is a new anti-inflammatory drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: placebo matching with ABX464

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: placebo matching with ABX464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 100mg
Description: ABX464 is a new anti-inflammatory drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
Study: NCT00638274

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air
Description: 3 mls used for identifying epidural space

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 3 mls of saline used to identify epidural space
Study: NCT02489851

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum block
Description: 0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tranversus Abdominis plane block
Description: 0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
Study: NCT03084094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Non invasive brain modulation at a 2mA current during 20minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Non invasive brain modulation at a 2mA current during 20minutes
Study: NCT03985462

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: very small embryonic-like stem cell
Description: Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: very small embryonic-like stem cell
Description: Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: very small embryonic-like stem cell
Description: Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
Study: NCT04423679

Intervention type: DEVICE
Intervention: Evalyn Brush
Description: a standard brush-based cervicovaginal self-collection device

Intervention type: DEVICE
Intervention: Evalyn Brush
Description: a standard brush-based cervicovaginal self-collection device
Study: NCT03961139

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Method of feeding; continuous feeding OR bolus feeding
Description: CF: Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.~BF: Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Method of feeding; continuous feeding OR bolus feeding
Description: CF: Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.~BF: Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes.
Study: NCT03082443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic group
Description: The group will take place in six meetings lasting one hour. At the end of the intervention, a new group will be started.~Issues related to illness, cardiopulmonary rehabilitation, aroused feelings and aspects of food education will be addressed, with the objective of improving nutritional profile, quality of life and reduction of stress level. During the meeting they will be constantly encouraged to express their feelings, doubts and exchanges of experiences.~In the first individual care (both groups) an initial consultation will be performed when the sociodemographic and anthropometric data will be collected and the instruments will be applied: Lipp Adult Stress Inventory, SF-12 Quality of Life Assessment Questionnaire and Questionnaire Of Food Frequency. After three months, all participants will be reassessed by the psychologist and nutritionist and anthropometric data will be collected and the instruments applied again.
Study: NCT04493944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culinary workshop
Description: A 3-hour culinary workshop will be led by a chef. The aim of this workshop will be to develop participants' culinary skills related to the preparation and consumption of recipes based on seaweeds, through various practical activities in the kitchen (starter, main course, dessert). An evaluation questionnaire will be completed at the end of the workshop.
Study: NCT00312728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be \< 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First-Line Chemotherapy Agents
Description: Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second-Line Chemotherapy Agents
Description: Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline.
Study: NCT02407665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM
Study: NCT02331316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily extra water intake
Description: Intervention-A: Timing of assigned daily extra water intake specified~Intervention-B: Daily extra water assigned at any time during 24 hour period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily extra water intake
Description: Intervention-A: Timing of assigned daily extra water intake specified~Intervention-B: Daily extra water assigned at any time during 24 hour period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily extra water intake
Description: Intervention-A: Timing of assigned daily extra water intake specified~Intervention-B: Daily extra water assigned at any time during 24 hour period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily extra water intake
Description: Intervention-A: Timing of assigned daily extra water intake specified~Intervention-B: Daily extra water assigned at any time during 24 hour period
Study: NCT02022891

Intervention type: BEHAVIORAL
Intervention: systematic psychological care
Description: Prevention treatment plan that provides systematic medical and psychological care at routine pediatric consultations for SCD. Bio-psychosocial paradigm applied at pediatric consultations.
Study: NCT02327728

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A injection (5 sites: 12.5U)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection (4 sites: 10U)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A 12.5U

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A 10U
Study: NCT01307228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Systems Evidence
Description: Health Systems Evidence (HSE) contains over 1400 research syntheses about governance, financial and delivery arrangements within health systems and about implementation strategies relevant to health systems. The syntheses have been: 1) categorized by topic, type of synthesis, and type of question addressed; 2) coded by the last year in which searches for studies were conducted and by the countries in which included studies were conducted; 3) rated for quality; and 4) linked to publicly available user-friendly summaries, scientific abstracts, and full-text reviews. We identified systematic reviews in HSE that are not accessible to study participants and developed a mechanism to reimburse publishers for full-text downloads of these reviews.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Systems Evidence
Description: Health Systems Evidence (HSE) contains over 1400 research syntheses about governance, financial and delivery arrangements within health systems and about implementation strategies relevant to health systems. The syntheses have been: 1) categorized by topic, type of synthesis, and type of question addressed; 2) coded by the last year in which searches for studies were conducted and by the countries in which included studies were conducted; 3) rated for quality; and 4) linked to publicly available user-friendly summaries, scientific abstracts, and full-text reviews. We identified systematic reviews in HSE that are not accessible to study participants and developed a mechanism to reimburse publishers for full-text downloads of these reviews.
Study: NCT00665691

Intervention type: OTHER
Intervention: Nutritional Screening Tools
Description: To compare the nutrition risk identification abilities of two nutrition screening tools: PEDSGA tool and the standard assessment tool.
Study: NCT03774706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: two tablets misoprostol 400 μg sublingual

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: two tablets misoprostol 400 μg sublingual

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: two ampoules of tranexamic acid (1gm in 10 ml) in 100ml saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to tranexamic acid
Description: placebo to tranexamic acid (110 ml saline)
Study: NCT00085644

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab (D2E7)
Description: Adalimumab 40 mg every other week, subcutaneous

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo every other week, subcutaneous
Study: NCT01487863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.
Study: NCT02174328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid once a day until 36 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day until 36 week
Study: NCT05923151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The cranial-caudal mixed medial approach
Description: Expose the fusion fascia of Transverse colon mesocolon and stomach, and cut the gastrocolic ligament. The mesentery of Transverse colon was dissociated from the medial side to the lateral side along the gastroepiploic vessels to expose the branches of Henle's trunk and the right colon vessels. The dorsal mesentery of the small intestine is cut along the yellow white line, and free cephalically along the Toldt space to separate the posterior space of the Ascending colon and the anterior space of the pancreas and duodenum behind the Transverse colon. The right colon blood vessels were dissected along SMV from the projection of ileocolic blood vessels, and the blood vessels were cut off by high ligation, and the lymph nodes at the root of Mesentery were cleared. Through a small incision in the middle of the abdomen, the right colon and mesentery were completely removed to complete digestive tract reconstruction.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: The cranial-caudal mixed medial approach
Description: Expose the fusion fascia of Transverse colon mesocolon and stomach, and cut the gastrocolic ligament. The mesentery of Transverse colon was dissociated from the medial side to the lateral side along the gastroepiploic vessels to expose the branches of Henle's trunk and the right colon vessels. The dorsal mesentery of the small intestine is cut along the yellow white line, and free cephalically along the Toldt space to separate the posterior space of the Ascending colon and the anterior space of the pancreas and duodenum behind the Transverse colon. The right colon blood vessels were dissected along SMV from the projection of ileocolic blood vessels, and the blood vessels were cut off by high ligation, and the lymph nodes at the root of Mesentery were cleared. Through a small incision in the middle of the abdomen, the right colon and mesentery were completely removed to complete digestive tract reconstruction.
Study: NCT03058263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose of Neostigmine
Description: Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose of Neostigmine
Description: Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished
Study: NCT02958033

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Whole Breast irradiation Plus simultaneous tumor bed Boost
Description: hypo-fractionated irradiation for experimental group and normal fractionated irradiation for comprator group

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Breast irradiation Plus simultaneous tumor bed Boost
Description: hypo-fractionated irradiation for experimental group and normal fractionated irradiation for comprator group
Study: NCT00486889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alglucosidase alfa
Description: Dose: 20 mg/kg every 2 weeks; Route of administration: Intravenous infusion
Study: NCT02750501

Intervention type: DEVICE
Group type: OTHER
Intervention: RELiZORB (immobilized lipase) cartridge
Description: Hydrolyzing fats from enteral formula, ex vivo, with in-line enteral feed RELiZORB (immobilized lipase) cartridge

Intervention type: OTHER
Group type: OTHER
Intervention: Impact Peptide 1.5
Description: Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding
Study: NCT02772991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: troponin measurement
Description: Cardiac catheterization (for patients with \>50% lesions) or discharge or in patients with intermediate risk.
Study: NCT02777034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ER
Description: Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（\<2000ml/d）.

Intervention type: OTHER
Group type: OTHER
Intervention: UR
Description: Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（\>2000ml/d）.
Study: NCT01537289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pigtail catheter insertion (Cook)
Description: insertion of pigtail catheter to decompress pneumothorax

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chest tube (28-French)
Description: inserting chest tube to decompress pneumothorax
Study: NCT03700086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable negative wound pressure device (PICO)
Description: Application of a disposable negative wound pressure device for surgical site infection prevention.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPsite post-op visible standard sterile dressing
Description: Application of a standard sterile wound dressing.
Study: NCT04197817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JS002
Description: JS002, Subcutaneous or intravenous injection of a single dose of JS002, dose cohort according to ascending dose design

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo,Subcutaneous or intravenous injection of a single dose of placebo, dose cohort according to ascending dose design
Study: NCT04801381

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aquablation therapy
Description: Aquablation is carried out with the AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral laser enucleation
Description: Transurethral laser enucleation is performed according to the standard established at the respective test center. Included laser techniques: Holmium laser (HoLEP) and Thulium laser (ThuLEP).
Study: NCT04269681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: Experimental intervention (HFNC) The HFNC (AIRVO 2 - Fisher \& Paykel Healthcare, Auckland, New Zealand) consists of a device that allows FiO2 adjustable from 21 to 100% and that delivers a flow of humidified and heated gas up to 60 l / min and 37 degrees C of temperature.~The HFNC will be offered until resolution of the ARF or until decision by the assisting team and the patient and/or their legal guardian, for the suspension of the treatment due to intolerance, and/or worsening of the discomfort and / or dyspnea.~The HFNC should be offered to the patient in ARF as follows:~* Initial parameters: Flow 45 ml / L, FiO2 50%, AIRVO 37oC temperature;~* Titrate the flow up to 60ml / L or up to the maximum tolerated;~* Titrate FiO2 to maintain SatO2 between 92% to 98%, starting with 50%;~* Keep the AIRVO temperature at 37oC, if not possible, acceptable down to 34oC.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard respiratory support
Description: The patient randomized to standard respiratory support will be placed on conventional low flow oxygen therapy according to the center's standard of care aiming at SpO2 90 - 98% and improvement of dyspnea. For cases refractory to oxygen therapy, keeping SpO2 below 90% or if dyspnea does not improve, non-invasive positive pressure ventilation (NIPPV) may be offered at the discretion of the assistant team. NIPPV will be performed with the patient in a supine position at 45 degrees. The mask will be facial (oronasal or full face) with an appropriate size for each patient and adapted in a way to minimize leakage. A hydrocolloid dressing can be placed over the nose in order to avoid ulcerations and increase comfort. The NIPPV will be performed with the help of a ventilator with inspiratory and expiratory circuits or with Bilevel devices with a single circuit and exhalation valve according to the availability of each center.
Study: NCT01324531

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bankart repair and remplissage
Description: Bankart repair may be completed before or after remplissage. While maintaining camera in anterior-superior portal drill guide and anchor cannula is placed through the posterior portal into remplissage site. Anchor cannula with obturator is passed through infraspinatus tendon and posterior capsule via pre-existing portal, and first anchor is placed in inferior aspect of Hill-Sachs lesion.Once anchor is inserted, penetrating grasper is passed through tendon and posterior capsule, 1 cm inferior to the initial portal entry site, to grasp and pull 1 suture limb.Second anchor is placed in superior aspect of Hill-Sachs lesion and grasper penetrator is used in same fashion to pass 1 suture limb 1 cm superior to initial portal entry site. The inferior suture is tied first with knots remaining extraarticular in the subdeltoid space. The superior suture is tied to complete remplissage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bankart repair
Description: Bankart repair based on surgeon's preference